Financial Performance - Revenue for Q1 2024 was CNY 10,747,829.83, a significant decrease of 78.94% from CNY 51,045,814.36 in Q1 2023[12] - Net profit attributable to shareholders was a loss of CNY 3,342,147.31, down 143.49% from a profit of CNY 7,684,095.67 in the same period last year[12] - Operating profit for the same period was -4.04 million yuan, down 145.53% year-on-year, attributed to changes in market demand leading to decreased product revenue[15] - The net profit for the first quarter of 2024 was -3.50 million yuan, a decrease of 145.57% year-on-year, primarily due to a decline in revenue and gross margin[15] - The company's total comprehensive income for Q1 2024 was -¥4,077,480.89, compared to ¥7,982,611.80 in Q1 2023, highlighting a drastic shift in overall financial performance[52] Cash Flow - Operating cash flow for the quarter was a negative CNY 11,430,013.86, representing a decline of 305.55% compared to a negative CNY 2,818,387.26 in Q1 2023[12] - The net cash flow from operating activities was -12,258,376.66, compared to -2,433,742.72 in the previous year, indicating a significant decline[56] - Cash inflow from financing activities amounted to 12,589,419.41, while cash outflow was 568,649.24, resulting in a net cash flow of 12,020,770.17, compared to -1,620,487.88 previously[56] - The company reported a significant decrease in cash and cash equivalents, with a net decrease of 2,604,906.49 compared to -51,893,336.39 last year[56] Assets and Liabilities - Total assets increased by 3.66% to CNY 474,853,107.79 as of March 31, 2024, compared to CNY 458,091,452.82 at the end of 2023[12] - Total liabilities increased to CNY 195,129,520.70 from CNY 174,968,345.64, reflecting a rise of approximately 11.5%[45] - Current assets increased to CNY 290,555,082.54 as of March 31, 2024, up from CNY 273,910,270.25 on December 31, 2023, representing a growth of approximately 6.4%[43] - The company's total assets reached CNY 474,853,107.79, up from CNY 458,091,452.82, indicating a growth of about 3.5%[45] Shareholder Information - The total number of ordinary shares was 68.5 million, with 37.80% being unrestricted shares and 62.20% being restricted shares[19] - Major shareholders include Bi Chunguang with 26.72% and Bianjing with 19.85% of the shares[20] - There were no pledged or judicially frozen shares among the major shareholders[22] Research and Development - Research and development expenses increased by 46.57% to CNY 1,999,529.25, reflecting the company's commitment to enhancing R&D efforts[14] - Research and development expenses for Q1 2024 were CNY 1,999,529.25, compared to CNY 1,364,229.54 in Q1 2023, representing an increase of approximately 46.5%[49] Debt and Financing - The company's debt-to-asset ratio rose to 41.09% from 38.20% year-over-year, indicating increased leverage[12] - Short-term borrowings rose by 44.38% to CNY 40,955,897.22, driven by the need for working capital[14] - The company maintained its long-term borrowings at CNY 26,400,000.00, unchanged from the previous year[48] Other Financial Metrics - The weighted average return on equity dropped to -1.19% from 7.61% in the previous year, indicating a decline in profitability[12] - The company reported a credit impairment loss of CNY -417,522.35 in Q1 2024, worsening from CNY -333,763.53 in Q1 2023[50] - Total operating costs for Q1 2024 amounted to CNY 17,378,642.04, compared to CNY 42,403,116.82 in Q1 2023, indicating a decrease of about 58.9%[49]
春光药装(838810) - 2024 Q1 - 季度财报